| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Nurix Therapeutics, Inc. (NRIX) have been net sellers, shedding 49,260 shares worth roughly $1.2M on balance. In the past 30 days, 0 insiders bought and 4 sold.
All 4 insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 123.5K | $3.19M | -6,861 | |
| CFO | 47.5K | $1.23M | -2,834 | |
| Other | 15.3K | $395.9K | -3,957 | |
| Dir | 10.8K | $277.6K | -22,583 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE | 4,895 | $16.60 | $81,249.16 | -5.5% | +1.1% | - | |
| Jan 20, 2026 | Christine Ring75 | Chief Legal Officer | Sale+OE10b5-1 | 3,760 | $18.42 | $69,273.11 | -6.9% | -6.6% | - | |
| Dec 18, 2025 | Christine Ring75 | Chief Legal Officer | Sale+OE10b5-1 | 3,760 | $17.90 | $67,314.32 | -6.9% | -16.4% | - | |
| Nov 24, 2025 | Christine Ring75 | Chief Legal Officer | Sale+OE10b5-1 | 37,600 | $17.07 | $641,696.64 | -42.5% | -10.3% | - | |
| Nov 3, 2025 | Hans van Houte56 | Chief Financial Officer | Sell10b5-1 | 6,284 | $12.56 | $78,931.44 | -14.3% | +35.4% | +114.9% | |
| Oct 30, 2025 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 3,130 | $12.80 | $40,053.67 | -6.7% | +39.8% | +112.2% | |
| Oct 30, 2025 | Christine Ring75 | Chief Legal Officer | Sale+OE | 3,644 | $12.80 | $46,631.17 | -6.7% | +39.8% | +112.2% | |
| Oct 30, 2025 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE | 4,087 | $12.80 | $52,300.11 | -5.1% | +39.8% | +112.2% | |
| Aug 1, 2025 | Hans van Houte56 | Chief Financial Officer | Sell10b5-1 | 5,402 | $11.03 | $59,597.57 | -13.2% | +15.8% | +110.2% | |
| Jul 30, 2025 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 4,304 | $12.01 | $51,695.34 | -9.5% | +0.2% | - |